Imaging of Neuroendocrine Tumors With PET and Fluoro-18-DOPA (F-DOPA)

Completed · Not applicable

Conditions studied: Neuroendocrine Tumors

In brief

Imaging of neuroendocrine (NETs), such as carcinoids and pheochromocytomas (PHEOs), is suboptimal, limiting curative treatment. The investigators wanted to explore the use of PET and F-DOPA i.v. for the localization of these types of neoplasms. The investigators used a similar protocol as they had used for PET (Positron emission tomography) or FDG (Fludeoxyglucose) imaging in oncologic patients. F-DOPA, prepared according to United States Pharmacopeia (USP) guidelines, was approved by the North Shore University Hospital Radiation Safety Committee in 1989 and 1994 for the study of neurological diseases and used uneventfully.

Key facts

Study ID
NCT02539433
Run by
Northwell Health
People needed
22
Starts
2003-12-01
Expected to finish
2015-05-01
Last updated by the study team
2015-09-03

Who can join

Age: 23 and older, up to 81. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.